APA (7th ed.) Citation

N, S., FE, T., AH, G., T, H., M, H., Y, M., . . . AS, D. G. (2024). Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis. Frontiers in immunology, 15, 1377911. https://doi.org/10.3389/fimmu.2024.1377911

Chicago Style (17th ed.) Citation

N, Sugiyama, et al. "Individual and Population-level Variability in HLA-DR Associated Immunogenicity Risk of Biologics Used for the Treatment of Rheumatoid Arthritis." Frontiers in Immunology 15 (2024): 1377911. https://doi.org/10.3389/fimmu.2024.1377911.

MLA (9th ed.) Citation

N, Sugiyama, et al. "Individual and Population-level Variability in HLA-DR Associated Immunogenicity Risk of Biologics Used for the Treatment of Rheumatoid Arthritis." Frontiers in Immunology, vol. 15, 2024, p. 1377911, https://doi.org/10.3389/fimmu.2024.1377911.